HIV Infected Research Studies:
- 1. Theratechnologies, Inc - Diabetic Retinopathy in HIV Subjects Treated with EGRIFTA (EMR 200147-500): A prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate whether EGRIFTA® (tesamorelin for injection), 2 mg oce daily SC, increased the risk of development or progression of diabetic retinopathy when administered to HIV-infected subjects with abdominal lipohypertrophy and concomitant diabetes. Duration of this study is approx. 3 years.
- AbbVie – HCV/HIV Treatment Study (M14-004): A Randomized, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 (HIV-1) Co-infection (TURQUOISE-I). Treatment duration is either 12 or 24 weeks and follow-up is 48 weeks. Total duration of study is approx. 72 weeks ( 1½ years).
- EGRIFTA Observational Study (EMR-200147-501): A phase 4, observational, multicenter, 10-year prospective cohort safety study comparing subjects with HIV-associated abdominal lipohypertrophy exposed to EGRIFTA® (tesamorelin for injection) to a similar group of subjects not exposed to EGRIFTA®. Duration of the study is 10 years of observation. Subject will be seen every 6 months.
- HIV Research Database: This study is being done to create a database for future medical research on HIV disease and related conditions.
General Population Study:
- INPATIENT: Actelion C-Diff Study (AC-061A302): A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid versus Vancomycin in subjects with Clostridium difficile associated diarrhea. Duration of this study is up to 44 days; or up to 88 days for subjects participating in the re-treatment extension with Cadazolid.
- FLU-IVIG Study (INSIGHT 006): Anti-Influenza Hyperimmune Intravenous Immunoglobulin Study. Duration of this study is 28 days. The subject is randomized in a 1:1 allocation to either IVIG plus standard of care (SOC) therapy or to placebo for IVIG (a comparable volume of normal saline) plus SOC